Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Researchers are exploring strategies to alter the gut microbiome to improve patients’ responses to immunotherapy. New ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

Real-world data show that adjuvant therapy, not complete nodal dissection, is crucial for preventing relapse in patients with stage III melanoma.

The Inflation Reduction Act (IRA) is expected to profoundly influence the clinical development strategies of pharma companies ...

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of ...

Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that originates from Merkel cells, which are neuroendocrine ...

The Merkel cell carcinoma market is poised for steady growth, with a strong CAGR projected from 2024 to 2034. This expansion across the 7MM will be driven by the launch of innovative therapies ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...